Dive Brief: Early next year, Spark Therapeutics Inc.’s gene therapy Luxturna could become the first such treatment for an inherited condition to win approval in the U.S., bringing with it new hope for patients with a rare form of childhood blindness. At the same time, the one-time treatment will likely command a premium price, putting...